<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00864175</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 7839-202</org_study_id>
    <nct_id>NCT00864175</nct_id>
  </id_info>
  <brief_title>Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer</brief_title>
  <official_title>A Phase 1/2, Modified Dose Escalation, Open Label Trial to Determine the Therapeutic Effect and Safety of INCB007839 Combined With Trastuzumab in Patients With Previously Untreated HER2 Positive Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, modified dose escalation, open label trial with the objectives of: (1)
      Determining a safe optimal dose of INCB007839 in combination with trastuzumab and docetaxel
      (2) Determining clinical efficacy and safety of INCB007839 in combination with trastuzumab
      and docetaxel.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Incyte suspended development of the compound.
  </why_stopped>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (complete + partial response) using RECIST (Response Evaluation Criteria in Solid Tumor) criteria</measure>
    <time_frame>Day 1 of each completed subsequent 21-day treatment cycle and the End of Study Visit.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the plasma pharmacokinetic (PK) profile of INCB007839 and trastuzumab when given in combination</measure>
    <time_frame>Monthly</time_frame>
    <description>For Cycle 1, PK samples to be collected on Day 8 and Day 15 at pre-dose the morning dose of INCB007839. For Cycles 2, 3 and 4, PK will be collected as a single sample, obtained at pre-dose, on Day 1. PK samples will not be collected at Cycle 5 or later.
o. For Cycle 1, PD samples to be collected at time of screening and at pre-dose on Day 1, Day</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment A - INCB007839 and Trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCB007839 100 mg BID and trastuzumab
In Cycle 1, trastuzumab will be administered at a loading dose of 8 mg/kg as a 90 minute intravenous infusion on Day 8. In all subsequent 21-day cycles, trastuzumab will be administered at 6 mg/kg as a 90 minute intravenous infusion on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B - INCB007839 and Trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCB007839 200 mg BID and trastuzumab
In Cycle 1, trastuzumab will be administered at a loading dose of 8 mg/kg as a 90 minute intravenous infusion on Day 8. In all subsequent 21-day cycles, trastuzumab will be administered at 6 mg/kg as a 90 minute intravenous infusion on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C - INCB007839 and Trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCB007839 300 mg BID and trastuzumab
In Cycle 1, trastuzumab will be administered at a loading dose of 8 mg/kg as a 90 minute intravenous infusion on Day 8. In all subsequent 21-day cycles, trastuzumab will be administered at 6 mg/kg as a 90 minute intravenous infusion on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D - INCB007839 and Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCB007839 300mg BID with docetaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB007839</intervention_name>
    <description>100 mg BID</description>
    <arm_group_label>Treatment A - INCB007839 and Trastuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB007839</intervention_name>
    <description>200 mg BID</description>
    <arm_group_label>Treatment B - INCB007839 and Trastuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB007839</intervention_name>
    <description>300 mg BID</description>
    <arm_group_label>Treatment C - INCB007839 and Trastuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB007839</intervention_name>
    <description>300 mg BID</description>
    <arm_group_label>Treatment D - INCB007839 and Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
    <description>trastuzumab will be administered at a loading dose of 8 mg/kg as a 90 minute intravenous infusion on Day 8. In all subsequent 21-day cycles, trastuzumab will be administered at 6 mg/kg as a 90 minute intravenous infusion on Day 1.</description>
    <arm_group_label>Treatment A - INCB007839 and Trastuzumab</arm_group_label>
    <arm_group_label>Treatment B - INCB007839 and Trastuzumab</arm_group_label>
    <arm_group_label>Treatment C - INCB007839 and Trastuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>Treatment D - INCB007839 and Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed metastatic breast carcinoma that is HER2
             positive

          -  Measurable disease as defined by the RECIST criteria

          -  Life expectancy greater than or equal to 6 months

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

        Exclusion Criteria:

          -  Received any anticancer medications in the 28 days prior to enrollment into this study

          -  Received any anticancer medications for cancers other than breast cancer within 6
             months prior to enrollment in this study.

          -  History of deep venous thrombosis within the last year

          -  Contraindication to low dose warfarin therapy

          -  Clinically significant cardiomyopathy

          -  Prior treatment with INCB007839 or trastuzumab or lapatinib
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bijyoyesh Mookerjee, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Visakhapatnam</city>
        <state>Andhra Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Delhi</city>
        <state>Ansari Nagar</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mangalore</city>
        <state>Attavar</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hyderabaad</city>
        <state>Punjagutta</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangalore</city>
        <state>Ram Nagar</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Delhi</city>
        <state>Rohini</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Delhi</city>
        <state>Vasundhara Enclave</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bhopal</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kolkata</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashik</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2009</study_first_submitted>
  <study_first_submitted_qc>March 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2009</study_first_posted>
  <disposition_first_submitted>June 18, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>June 18, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 22, 2010</disposition_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

